Creo Medical (CREO) AI Stock Analysis

Creo Medical

(LSE:CREO)

Select Model

Rating:43Neutral

Price Target:GBX 11.00▼(-4.68% Downside)

Action:reiterated

Date:10/01/26

The score is held down primarily by weak financial performance (large operating losses and sustained cash burn) and bearish technicals (price below key moving averages with negative MACD). A relatively manageable leverage position supports the balance sheet, but the negative P/E and lack of a stated dividend yield provide limited valuation support.

Positive Factors

Manageable leverageRelatively low leverage gives Creo greater financial flexibility while it scales its medical-device platform. A sizable equity base can help absorb continued investment needs and reduces the immediate balance-sheet pressure associated with high debt servicing obligations.

Negative Factors

Persistent operating lossesLarge recurring operating losses show that the current cost base remains well ahead of revenue scale. Unless growth translates into meaningful operating leverage, Creo may continue needing substantial investment before its core activities can generate sustainable profitability.

Creo Medical (CREO) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: GBP 51.09M
Dividend Yield: ―
Average Volume (3M): 707.99K
Price to Earnings (P/E): -2.5
Beta (1Y): 1.21
Revenue Growth: ―
EPS Growth: ―
Country: UK
Employees: 104
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Creo Medical Business Overview & Revenue Model

Company Description

Creo Medical Limited, a UK-based enterprise and subsidiary of Creo Medical Group plc, specializes in the innovation and creation of electrosurgical medical devices for surgical endoscopy applications. Founded in 2003 as MicroOncology Ltd and headquar...

How the Company Makes Money

Creo Medical makes money primarily through the sale of medical devices and associated consumables used in endoscopic procedures. Key revenue streams include: (1) Capital equipment/platform sales: revenue from selling its electrosurgical generator/sys...

Creo Medical Financial Statement Overview

Summary

Balance sheet strength is a relative positive (low leverage and sizable equity), but overall financial quality is constrained by very large operating losses and consistently negative operating/free cash flow. Revenue improved in 2025, yet profitability and cash generation have not inflected, keeping financial risk elevated.

Income Statement

36Negative

Balance Sheet

72Positive

Cash Flow

28Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.00M	6.00M	4.00M	4.00M	27.17M	25.16M
Gross Profit	1.90M	1.40M	1.90M	15.30M	10.01M	9.02M
EBITDA	-19.70M	-19.70M	-26.10M	-20.70M	-27.62M	-27.54M
Net Income	5.30M	5.30M	-28.70M	-21.70M	-26.94M	-24.59M
Balance Sheet
Total Assets	59.10M	59.10M	65.00M	76.60M	75.34M	100.61M
Cash, Cash Equivalents and Short-Term Investments	12.40M	12.40M	8.70M	18.50M	13.10M	43.53M
Total Debt	4.10M	4.10M	4.40M	8.30M	11.70M	10.56M
Total Liabilities	9.10M	9.10M	22.60M	16.80M	25.93M	27.29M
Stockholders Equity	50.00M	50.00M	42.40M	59.80M	49.40M	73.32M
Cash Flow
Free Cash Flow	-18.90M	-20.00M	-22.60M	-22.80M	-28.26M	-32.10M
Operating Cash Flow	-18.90M	-19.10M	-22.20M	-21.60M	-24.99M	-25.98M
Investing Cash Flow	19.40M	19.40M	15.30M	-18.30M	-6.03M	-7.87M
Financing Cash Flow	-700.00K	-700.00K	16.20M	29.80M	400.00K	31.99M

Creo Medical Technical Analysis

Technical Analysis SentimentNeutral

Last Price11.54

Price Trends

50DMA11.68Negative

100DMA12.63Negative

200DMA13.05Negative

Market Momentum

MACD-0.04Negative

RSI57.26Neutral

STOCH70.80Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CREO, the sentiment is Neutral. The current price of 11.54 is above the 20-day moving average (MA) of 10.77, below the 50-day MA of 11.68, and below the 200-day MA of 13.05, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 57.26 is Neutral, neither overbought nor oversold. The STOCH value of 70.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:CREO.

Creo Medical Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:CREO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:TSTL	80Outperform	GBP 194.70M	24.28	23.05%	3.51%	10.02%	19.83%
GB:SN	72Outperform	GBP 9.27B	19.52	12.25%	2.66%	2.17%	27.33%
GB:AMS	67Neutral	GBP 611.34M	166.18	1.44%	1.66%	6.05%	-60.00%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:CREO	43Neutral	GBP 51.09M	-2.51	-38.29%	―	―	―
GB:SUN	40Underperform	GBP 3.73M	-4.00	-15.47%	―	-3.68%	20.00%

* Healthcare Sector Average

Performance Comparison

GB:CREO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:CREO	Creo Medical	11.38	0.13	1.11%
GB:AMS	Advanced Medical Solutions	282.50	67.49	31.39%
GB:SUN	Surgical Innovations Group Plc	0.40	-0.18	-31.03%
GB:TSTL	Tristel plc	405.00	58.67	16.94%
GB:SN	Smith & Nephew (UK)	1107.50	-251.88	-18.53%

Creo Medical Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and Financing

Creo Medical Cuts Costs and Lifts Revenue as Endoscopy Devices Gain Traction

Positive

Sep 30, 2026

Creo Medical reported unaudited interim results for the six months to 30 June 2026 showing strong progress in tightening its cost base while accelerating commercial adoption of its advanced endoscopy tools. Revenue rose 45% to £3.2 million, unde...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026

Creo Medical AI Stock Analysis